Novartis says EU approves expanded use of Glivec

Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive (GIST)," Novartis said in a statement.

"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the ," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

add to favorites email to friend print save as pdf

Related Stories

'Rare' cancers in the spotlight at major European conference

Feb 24, 2010

More should be done across Europe to ensure that people with rare forms of cancer are not denied access to the best possible treatment, say the organizers of a major European cancer conference to be held in Milan on 9 and ...

Drug shows promise as new treatment for gut tumor

Jan 11, 2010

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh ...

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments